Jeffrey Gershenwald

17PUBLICATIONS
190CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Law, science and technologyHaematological tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 02, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

|Jul 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.

Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff

|Nov 21, 2024
Bills to Restrict Access to and Harm From Indoor Tanning Facilities in US State Legislatures, 1992‒2023.

David B Buller, Julia Berteletti, Carolyn Heckman

|Feb 05, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.

Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni

|May 10, 2023
Mitotic rate in primary cutaneous melanoma: Cell division matters.

Jeffrey E Gershenwald

|Jan 10, 2023
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.

Christopher P Vellano, Michael G White, Miles C Andrews

Pageof 3

Frequent Collaborators

9 joint publications

Michael A Davies

9 joint publications

Alexander Lazar

7 joint publications

Jennifer A Wargo

7 joint publications

P Andrew Futreal